You probably know someone who has struggled with the sudden heat waves, night sweats and broken sleep that can define menopause.
For many women, hormone therapy helps turn that experience around. But cost and the hassle of daily pills have kept it out of reach for others.
On October 20, 2026, the FDA approved the first generic version of Climara Pro, a once-weekly skin patch that treats menopause symptoms and helps protect against bone loss. The generic is made by Zydus Pharmaceuticals.
Generics now account for roughly nine out of ten prescriptions filled in the United States, and they usually cost far less than their brand-name counterparts. That price difference is why this approval matters for women managing menopause.
Also read: 8 warning signs your gut trouble could be Crohn's disease, not just IBS
How the patch works and who it is for
The patch delivers two hormones through the skin. Estradiol is a form of estrogen that eases hot flashes and night sweats.
'It also helps slow the bone loss that often follows menopause. Levonorgestrel is a progestin that protects the lining of the uterus.
The patch is approved for women who still have their uterus. Those who have had a hysterectomy do not usually need the progestin component and are often prescribed estrogen alone.
It is cleared for moderate to severe hot flashes and night sweats, which doctors group under the medical term vasomotor symptoms. The same patch is also approved to prevent the bone-thinning disease osteoporosis after menopause.
Also read: How eating sweet potatoes every day may affect your gut, eyes and blood sugar
Why a weekly patch matters
The FDA announcement emphasized the convenience of weekly dosing over a daily pill. Michael Davis, director of the agency's Center for Drug Evaluation and Research, said, "Once-weekly dosing can make a real difference in how patients manage their care."
In coverage by Healio, Nanette Santoro of the University of Colorado School of Medicine said, "For many women, this is as good as it gets."
Brand-name Climara Pro, made by Bayer, has been on the US market for years. Zydus has not announced when its generic will reach pharmacies or at what price, but generic approvals typically bring prices down as more companies enter a market.
Important safety information
Common side effects reported with the therapy include skin reactions where the patch is applied, breast tenderness, headache and vaginal bleeding.
Also read: How many pull-ups should you be able to do? Amount sorted by age and sex
The FDA notes that women with a history of breast cancer, blood clots or undiagnosed abnormal bleeding should not use the patch. Anyone considering hormone therapy should talk with a doctor about their personal risk profile.
Also read: If your legs won't stop moving in late pregnancy, your depression risk may triple
This article is made and published by Mie Hermansen, who may have used AI in the preparation.